The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q1 2023 call → NOWe need to determine if management conveys that the reported results do not represent the business as it is actually running today, i.e., that the reported period is stale relative to the operating present. Look for management's own words indicating a gap between the reported numbers and current business state, grounded in concrete current activity, not just future plans. In the transcript, management discusses Q1 2023 results. They mention progress in various channels, but also note that Q1 was a transition period. For example, they say: "we are expecting the year to be an inflection point" and "we look forward to seeing the continued evolution of our channel strategy" - that's future. But they also say: "Our disciplined execution allowed us to make progress during the first quarter" and "we continue to leverage the investments we have already made" - that's about the quarter. Key points: They mention that DTC productivity improved, but they decreased sales reps. They say: "while we decreased the number of sales reps, Q1 2023 delivered solid sequential growth in the teens on a per rep basis" - that's about the quarter. They also mention that they are on track for Rove 4 launch in back half of 2023, and Rove 6 in Europe already launched. They secured reimbursements in Germany and France. They added two large private payers. They say: "We now can cover the COPD patient population out of approximately 160 million privately-covered lives." That's a current capability. But do they explicitly say that the reported results do not reflect the current business? They say: "While our revenue was in line with the expectations, we have communicated during our Q4 2022 earnings call, our gross margin and EBITDA performance were above our internal expectations." That's about the quarter. They also say: "We are expecting the year to be an inflection point" - that's future. They say: "we remain focused on delivering low to mid-single-digit revenue growth and return to positive adjusted EBITDA by the fourth quarter." That's guidance. They discuss that Q1 had some challenges in B2B due to remediation and market dynamics, but they are making progress. They say: "The start was a little bit softer, but we’re very encouraged by the progress that we’re making." That's about the quarter. They also say: "we have enough supply to meet the demand.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.